ClinicalTrials.gg

TargetBeta

PPARD

peroxisome proliferator activated receptor delta · also NUC1, NUCII, FAAR, NR1C2 · Peroxisome proliferator activated receptors

5 programs in company-led studies act on PPARD, from 5 companies: 5 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
elifibranorruleGenfitphase 3245 runningPPARAChEMBL
seladelparruleGilead Sciencesphase 3143 runningPPARAChEMBL
lanifibranorInventiva Pharmaphase 361 runningPPARA, PPARGthe company's pipeline
T3D-959ruleT3D Therapeuticsphase 331 runningPPARGChEMBL
chiglitazarruleChipscreen Biosciencesphase 390 runningPPARA, PPARGChEMBL

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.